Page 84 - Haematologica Vol. 110 - January 2025

ARTICLE - HCT in elderly AML
D. Niederwieser et al.
Acknowledgments
The authors would like to acknowledge Michael Cross PhD for language cross reading, the transplantation center physicians, nurses, and data managers for their continued help and in their constant improvement in their patients’ outcomes. We thank the local and central data managers for collecting patient data, in particular Yasmine Breiten- stein, Schrock, Annett and Kalina Berit (study manager, data manager, Center of Clinical Trials Leipzig), Marlies Groenendijk-Sijnke (study manager HOVON) and R. Hack, G. Droog-Bellis, M. Stals-Huls, D. van den Boom (local data managers HOVON).
Funding
The study was supported by the Deutsche Krebshilfe grant
References
1. Fitzmaurice C, Abate D, Abbasi N, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749-1768.
2. Heinicke T, Krahl R, Kahl C, et al. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. Ann Hematol. 2021;100(9):2387-2398.
3. McCurdy SR, Luger SM. Dose intensity for induction in acute myeloid leukemia: what, when, and for whom? Haematologica. 2021;106(10):2544-2554.
4. Medeiros BC, Satram-Hoang S, Hurst D, Hoang KQ, Momin F, Reyes C. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol. 2015;94(7):1127-1138.
5. Niederwieser D, Lang T, Krahl R, et al. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study. Ann Hematol. 2023;102(3):547-561.
6. Al-Ali HK, Jaekel N, Junghanss C, et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma. 2012;53(1):110-117.
7. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-629.
8. Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984-997.
9. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728-1740.
10. Erba H, Montesinos P, Vrhovac R, et al. Quizartinib prolonged survival vs. placebo plus in-tensive induction and consolidation therapy followed by single-agent continuation in patients aged 18-75 years with newly diagnosed FLT3-ITD+ AML. Hemasphere. 2022;6:1-2.
108830, grant support for data management by KWF-Dutch Cancer Society (grant no.: EMCR 2008-4332) and by the Swiss State Secretariat for Education, Research and Innovation (SERI) Switzerland.
Data-sharing statement
Individual participant data that underlie the results reported in this article (text, tables, figures, and appendices) will be shared after de-identification to researchers who provide a methodologically sound and ethically approved propos- al. Proposals can be submitted up to at least 36 months after article publication. Proposals should be directed to dirk.hasenclever@imise.uni-leipzig.de; to gain access, data requestors will need to sign a data access agreement.
11. Erba HP, Montesinos P, Kim H-J, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal- tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo- controlled, phase 3 trial. Lancet. 2023;401(10388):1571-1583.
12. Storb R, Gyurkocza B, Storer BE, et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2013;31(12):1530-1538.
13. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390-3400.
14. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101(4):1620-1629.
15. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplanta-tion from related and unrelated donors. J Clin Oncol. 2006;24(3):444-453.
16. Versluis J, Hazenberg CLE, Passweg JR, et al. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematol. 2015;2(10):e427-e436.
17. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;19(12):2304-2312.
18. Sorror ML, Sandmaier BM, Storer BE, et al. Long-term outcomes among older patients following nonmyeloablative conditioning
Haematologica | 110 January 2025
76